

Edgar Filing: BIOMERICA INC - Form 10-Q

BIOMERICA INC
Form 10-Q
October 15, 2008

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED AUGUST 31, 2008

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934

For the transition period from _____ to _____

Commission File Number: 0-8765

BIOMERICA, INC.

(Exact name of registrant as specified in its charter)

Delaware

95-2645573

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer
Identification No.)

1533 Monrovia Avenue, Newport Beach, California

92663

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number including area code: (949) 645-2111

(Not applicable)

(Former name, former address and former fiscal year,
if changed since last report.)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes No

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Edgar Filing: BIOMERICA INC - Form 10-Q

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company

Indicated by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date: 6,631,039 shares of common stock, par value \$.08, as of October 15, 2008.

BIOMERICA, INC.

INDEX

PART I

Item 1. Consolidated Financial Statements:

Consolidated Statements of Operations and Comprehensive Income (unaudited) - Three Months Ended August 31, 2008 and 2007..... 1 & 2

Consolidated Balance Sheet (unaudited) August 31 and (audited) May 31, 2008..... 3 & 4

Consolidated Statements of Cash Flows (unaudited) - Three Months Ended August 31, 2008 and 2007..... 5

Notes to Consolidated Financial Statements (unaudited) 6-9

Item 2. Management's Discussion and Analysis of Financial Condition and Selected Financial Data..... 10-12

Item 3. Quantitative and Qualitative Disclosures about Market Risk..... 12

Item 4. Controls and procedures..... 13

PART II Other Information..... 14

Item 1. Legal Proceedings..... 14

Item 1A. Risk Factors..... 14

Item 2. Unregistered Sales of Equity Securities & Use of Proceeds..... 14

Item 3. Defaults upon Senior Securities..... 14

Item 4. Submission of Matters to a Vote of Security Holders..... 14

Item 5. Other Information..... 14

Item 6. Exhibits..... 14

Signatures..... 15

Edgar Filing: BIOMERICA INC - Form 10-Q

PART I - FINANCIAL INFORMATION
SUMMARIZED FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS

BIOMERICA, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE INCOME (UNAUDITED)

	Three Months Ended August 31,	
	2008	2007
	-----	-----
Net sales	\$ 1,194,345	\$ 1,340,065
Cost of sales	(661,216)	(735,621)
Gross profit	533,129	604,444
Operating Expenses:		
Selling, general and administrative	338,883	320,283
Research and development	46,988	69,744
	-----	-----
	385,871	390,027
	-----	-----
Operating gain from operations	147,258	214,417
Other Expense (income):		
Interest (income) expense	9,671	12,543
Other income, net	(12,022)	(707,754)
	-----	-----
	(2,351)	(695,211)
	-----	-----
Income before income taxes	149,609	909,628
Income tax expense	8,797	24,242
	-----	-----
Net income	\$ 140,812	\$ 885,386
	=====	=====

1

BIOMERICA, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE INCOME (UNAUDITED) - Continued

Other comprehensive income, net of tax		
Unrealized gain on available-for-sale securities	\$ 25	\$ 34,299
	-----	-----
Comprehensive income	\$ 140,837	\$ 919,685

Edgar Filing: BIOMERICA INC - Form 10-Q

	=====	=====
Basic net income per common share	\$.02	\$.15
	=====	=====
Diluted net income per common share	\$.02	\$.13
	=====	=====
Weighted average number of common and common equivalent shares:		
Basic	6,587,114	5,952,730
	=====	=====
Diluted	7,096,130	7,070,187
	=====	=====

The accompanying notes are an integral part of these statements.

2

BIOMERICA, INC.
CONSOLIDATED BALANCE SHEET

	August 31, 2008 (unaudited) -----
Assets	
Current Assets	
Cash and cash equivalents	\$ 1,960,826
Available for-sale securities	380
Accounts receivable, less allowance for doubtful accounts of \$86,972 and \$84,206, respectively	524,003
Inventories, net	1,954,502
Prepaid expenses and other	87,446
Deferred tax asset.....	35,000

Total Current Assets	4,562,157
Property and Equipment, net of accumulated depreciation and amortization	381,294
Deferred Tax Asset.....	135,000
Other Assets	75,066

	\$ 5,153,517
	=====

The accompanying notes are an integral part of these statements.

3

BIOMERICA, INC.
CONSOLIDATED BALANCE SHEET - Continued

August 31,

Edgar Filing: BIOMERICA INC - Form 10-Q

	2008 (unaudited)

Liabilities and Shareholders' Equity	
Current Liabilities	
Accounts payable and accrued liabilities	\$ 469,161
Accrued compensation	471,568
Current portion of shareholder loan	--
Capital lease - short term portion	2,976
Equipment loan - short term portion	50,225

Total Current Liabilities	993,930
Loan for equipment purchase	101,521
Shareholders' Equity	
Common stock, \$0.08 par value authorized 25,000,000 shares, issued and outstanding 6,621,839 and 6,489,839 in at August 31, 2008 and May 31, 2008, respectively	529,746
Additional paid-in-capital	17,432,819
Accumulated other comprehensive loss	(7,373)
Common stock subscribed	--
Accumulated deficit	(13,897,126)

Total Shareholders' Equity	\$ 4,058,066

Total Liabilities and Shareholders' Equity	\$ 5,153,517
	=====

The accompanying notes are an integral part of these statements.

4

BIOMERICA, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

For the three months ended August 31,	2008	2007
	-----	-----
Cash flows from operating activities:		
Net income from continuing operations	\$ 140,812	\$ 88,000
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	21,048	1,000
Stock option expense	3,283	1,000
Provision for losses on accounts receivable	2,766	1,000
Changes in current assets and liabilities:		
Accounts Receivable	87,561	(23,000)
Inventories	(190,300)	1,000
Prepaid expenses and other assets	4,352	(2,000)
Accounts payable and other accrued liabilities	(4,380)	(9,000)
Accrued compensation	(15,547)	(9,000)
	-----	-----

Edgar Filing: BIOMERICA INC - Form 10-Q

Net cash provided by operating activities	49,595	47
	-----	-----
Cash flows from investing activities:		
Purchases of property and equipment	(32,762)	(
	-----	-----
Net cash used in investing activities	(32,762)	(
	-----	-----
Cash flows from financing activities:		
Paydown on shareholder loan	(95,936)	(1
Exercise of stock options and warrants	27,000	1
Payment of common stock subscribed	3,000	
Payments on capital lease	(1,204)	(
Payment of equipment loan	(11,247)	
	-----	-----
Net cash (used in) provided by financing activities	(78,387)	
	-----	-----
Net (decrease) increase in cash and cash equivalents	(61,554)	47
	-----	-----
Cash and cash equivalents at beginning of period	2,022,380	51
	-----	-----
Cash and cash equivalents at end of period	\$ 1,960,826	\$ 99
	=====	=====
Supplemental Disclosure of Cash Flow Information:		
Cash paid during the quarter for:		
Interest	\$ 10,062	\$
Taxes	--	
	=====	=====
Change in unrealized holding loss on available-for-sale securities	\$ (25)	\$ 3
	=====	=====

The accompanying notes are an integral part of these statements.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

August 31, 2008

(1) In December 2004, the Financial Accounting Standards Board ("FASB") Issued Statement of Financial Accounting Standards No. 123 (revised 2004), Share-Based Payment (SFAS No. 123R). SFAS No. 123R revised SFAS No. 123, Accounting For Stock-Based Compensation, and supersedes APB Opinion No. 25, Accounting for Stock Issued to Employees, and its related implementation guidance. SFAS No. 123R requires compensation costs related to share-based payment transactions to be recognized in the financial statement (with limited exceptions). The amount of compensation cost is measured based on the grant- date fair value of the equity or liability instruments issued. Compensation cost is recognized over the period that an employee provides service in exchange for the award. As of the beginning of fiscal 2007, June 1, 2006, the Company began using this method.

The Black Scholes option valuation model was developed for use in estimating the fair value of traded options which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly

Edgar Filing: BIOMERICA INC - Form 10-Q

subjective assumptions including the expected stock price volatility. Because the Company's employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management's opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.

For the three months ended August 31, 2008 and 2007 the Company expensed \$3,283 and \$6,581 of stock option expense due to SFAS 123(R) in its financial statements, respectively.

(2) The following summary presents the options and warrants granted, exercised, expired, cancelled and outstanding as of August 31, 2008:

	Number of Options and Warrants			Weighted
	Employee	Non-employee	Total	Average Exercise Price
	-----	-----	-----	-----
Outstanding				
May 31, 2008	1,346,958	155,166	1,502,124	\$ 0.76
Granted	--	--	--	--
Exercised	(100,000)	(20,000)	(120,000)	0.25
Cancelled or expired	(19,500)	--	(19,500)	0.69
	-----	-----	-----	-----
Outstanding				
August 31, 2008	1,227,458	135,166	1,362,624	\$ 0.81
	=====	=====	=====	=====

(3) The information set forth in these condensed consolidated statements is unaudited and may be subject to normal year-end adjustments. The information reflects all adjustments which, in the opinion of management, are necessary to present a fair statement of the consolidated results of operations of Biomerica, Inc., for the periods indicated. It does not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flow in conformity with generally accepted accounting principles. All adjustments that were made are of normal recurring nature.

(4) The unaudited Consolidated Financial Statements and Notes are presented as permitted by the requirements for Form 10-Q and do not contain certain information included in our annual financial statements and notes. The Consolidated Balance Sheet data as of May 31, 2008 was derived from audited financial statements. The accompanying interim Consolidated Financial Statements should be read in conjunction with the financial statements and related notes included in our Annual Report on Form 10-KSB filed with the Securities and Exchange Commission (SEC) for the fiscal year ended May 31, 2008. The results of operations for our interim periods are not necessarily indicative of results to be achieved for our full fiscal year.

6

(5) Aggregate cost exceeded market value of available-for-sale securities by approximately \$7,373 and \$7,398 at August 31 and May 31, 2008, respectively.

(6) Inventories are stated at the lower of cost (first-in, first-out method) or market and consist primarily of biological chemicals. Cost includes raw materials, labor, manufacturing overhead and purchased products. Market is

Edgar Filing: BIOMERICA INC - Form 10-Q

determined by comparison with recent purchases or net realizable value. Such net realizable value is based on forecasts for sales of the Company's products in the ensuing years. The industry in which the Company operates is characterized by technological advancement and change. Should demand for the Company's products prove to be significantly less than anticipated, the ultimate realizable value of the Company's inventories could be substantially less than the amount shown on the accompanying consolidated balance sheet.

Inventories approximate the following:

	August 31, 2008
Raw materials	\$ 736,392
Work in progress	683,714
Finished products	534,396
Total	\$ 1,954,502

Allowances for inventory obsolescence are recorded as necessary to reduce obsolete inventory to estimated net realizable value or to specifically reserve for obsolete inventory that the Company intends to dispose of.

(7) Earnings Per Share

Basic EPS is computed as net income divided by the weighted average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution that could occur from common shares issuable through stock options, warrants and other convertible securities.

The following table illustrates the required disclosure of the reconciliation of the numerators and denominators of the basic and diluted EPS computations.

	AUGUST 31, 2008	2007

Numerator:		
Income from continuing operations	\$ 140,812	\$ 885,386
=====		
Denominator for basic net income per common share	6,587,114	5,952,730
Effect of dilutive securities:		
Options and warrants	509,016	1,117,457

Denominator for diluted net income per common share	7,096,130	7,070,187
=====		
Basic net income per common share	\$.02	\$ 0.15
=====		
Diluted net income per common share	\$.02	\$ 0.13
=====		

(8) In December 2007, the FASB issued SFAS No. 141R, Business Combinations. SFAS 141R establishes a defined measurement period that governs the time period within which the business combination must be reported. In addition, the revised

Edgar Filing: BIOMERICA INC - Form 10-Q

standard significantly expands the scope of disclosure requirements. SFAS No. 141R is effective for annual periods beginning after December 15, 2008. The Company does not believe that the adoption of SFAS No. 141R will have a material impact on its financial statements.

7

In December 2007, the FASB issued SFAS No. 160, Noncontrolling Interests in Consolidated Financial Statements--an amendment of ARB No. 51. This statement applies to all entities that prepare consolidated financial statements, except for non-profit organizations, but will affect only those entities that have an outstanding noncontrolling interest in one or more subsidiaries or that deconsolidate a subsidiary. SFAS No. 160 is effective for annual periods beginning December 15, 2008. The Company does not believe that the adoption of SFAS No. 160 will have a material impact on its financial statements.

In March 2008, the FASB issued SFAS No. 161, Disclosures about Derivative Instruments and Hedging Activities--an Amendment of FASB Statement No. 133. This Statement requires qualitative disclosures about objectives and strategies for using derivatives, quantitative disclosures about fair value amounts of and gains and losses on derivative instruments, and disclosures about credit-risk-related contingent features in derivative agreements. SFAS No. 161 is effective for financial statements issue years and interim periods beginning after November 15, 2008. The Company does not believe that the adoption of SFAS No. 161 will have a material impact on its financial statements.

In May 2008, the FASB issued SFAS No. 163, Accounting for Financial Guarantee Insurance Contracts. The new standard clarifies how FASB Statement No. 60, Accounting and Reporting by Insurance Enterprises, applies to financial Guarantee insurance contracts issued by insurance enterprises. The Statement is effective for financial statements issued for fiscal years beginning after December 15, 2008, and all interim periods within those fiscal years. The Company does not believe that the adoption of SFAS No. 163 will have any impact on its financial statements.

(9) Financial information about foreign and domestic operations and export sales is as follows:

	For the Three Months Ended	
	8/31/08	8/31/07
	-----	-----
Revenues from sales to unaffiliated customers:		
United States	\$ 191,000	\$ 335,000
Asia	280,000	318,000
Europe	680,000	648,000
South America	35,000	21,000
Middle East	7,000	4,000
Other	1,000	14,000
	-----	-----
	\$1,194,000	\$1,340,000
	=====	=====

No other geographic concentrations exist where net sales exceed 10% of total net sales.

(10) In April 2007 the board of directors granted a stock option for 25,000 options to a new Company director. The options vested one half immediately and then one quarter per year thereafter. The option is at the exercise price of

Edgar Filing: BIOMERICA INC - Form 10-Q

\$0.76 per share and expires in five years. Management assigned a value of \$11,632 to this option.

In April 2007 the board of directors granted stock options for 163,500 options to employees and consultants of the company. The options vested one half immediately and then one quarter per year thereafter. The options are at the exercise price of \$0.73 and expire in five years. Management assigned a value of \$72,489 to these options.

In May 2007 the board of directors granted stock options for 171,000 options to certain officers and employees. The options vested one half immediately and then one quarter per year thereafter. The options are at the exercise price of \$0.80 and expire in five years. Management assigned a value of \$78,895 to these options.

In July 2007 the board of directors granted a stock option for 25,000 options to a new Company director. The options vested one half immediately and then one quarter per year thereafter. The option is at the exercise price of \$0.78 per share and expires in five years. Management assigned a value of \$10,541 to this option.

In November 2007 the board of directors granted stock options for 16,000 options to various employees. The options vested one quarter immediately and then one quarter per year thereafter. The options are at the exercise price of \$1.30 per share and expire in five years. Management assigned a value of \$10,952 to these options.

During the year ended May 31, 2008, 557,625 options and warrants to purchase Biomerica, Inc., common stock were exercised. The options were at prices ranging from \$0.20 to \$0.73. The total proceeds to the Company were \$162,386.

8

During the quarter ended August 31, 2008, 120,000 warrants to purchase Biomerica, Inc. common stock were exercised. The warrants had an exercise price of \$0.25 per share. Total proceeds to the Company were \$30,000.

Options or warrants granted are assigned values according to current market value, using the Black-Scholes model for option valuation. The term used in the calculation of the options or warrants is the expected life of the option, taking into consideration cancellations, exercises and expirations. A discount rate equivalent to the expected life of the option is calculated using Treasury constant maturity interest rates. For the options granted in fiscal 2008 Biomerica used the simplified method (as defined in SAB 107) for calculating the expected life of an option because estimating the expected life is difficult based on historical data. The historical volatility of the stock is calculated using weekly historical closing prices for the length of the vesting period as reported by Yahoo Finance. For purposes of the SFAS 123R footnote disclosure, the Black-Scholes Model is also used for calculating employee options and warrants valuations.

When shares are issued for services or other non-cash consideration, fair value is measured using the current market value on the day of the Board of Directors approval of such issuance.

(11) In July 2008, the Company paid off the principal and interest balance owed on the shareholder note payable.

(12) Under its bylaws, the Company has agreed to indemnify its officers and directors for certain events or occurrences arising as a result of the officer

Edgar Filing: BIOMERICA INC - Form 10-Q

or director's serving in such capacity. The term of the indemnification period is for the officer's or director's lifetime. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited. However, the Company has a directors and officer liability insurance policy that limits its exposure and enables it to recover a portion of any future amounts paid.

As a result of its insurance policy coverage, the Company believes the estimated fair value of these indemnification agreements is minimal and has no liabilities recorded for these agreements as of August 31, 2008. The Company enters into indemnification provisions under (i) its agreements with other companies in its ordinary course of business, typically with business partners, contractors, and customers, landlords and (ii) its agreements with investors. Under these provisions the Company generally indemnifies and hold harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of the Company's activities or, in some cases, as a result of the indemnified party's activities under the agreement. These indemnification provisions often include indemnifications relating to representations made by the Company with regard to intellectual property rights. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is unlimited. The Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, the Company believes the estimated fair value of these agreements is minimal. Accordingly, the Company has no liabilities recorded for these agreements as of August 31, 2008.

(13) In June 2008 the Company incorporated in Mexico under the name of Biomerica de Mexico for the purpose of establishing our own mequiladora operation in Mexico at some time in the future.

(14) Subsequent Events

During September 2008 an employee exercised 4,200 options to purchase common stock at an exercise price of \$0.33 per share. Total proceeds to the Company were \$1,386.

During October 2008 an employee exercised 5,000 options to purchase common stock at an exercise price of \$0.40 per share. Total proceeds to the Company were \$2,000.

Item 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND SELECTED FINANCIAL DATA

CERTAIN INFORMATION CONTAINED HEREIN (AS WELL AS INFORMATION INCLUDED IN ORAL STATEMENTS OR OTHER WRITTEN STATEMENTS MADE OR TO BE MADE BY BIOMERICA) CONTAINS STATEMENTS THAT ARE FORWARD-LOOKING, SUCH AS STATEMENTS RELATING TO ANTICIPATED FUTURE REVENUES OF THE COMPANY AND SUCCESS OR CURRENT PRODUCT OFFERINGS. SUCH FORWARD-LOOKING INFORMATION INVOLVES IMPORTANT RISKS AND UNCERTAINTIES THAT COULD SIGNIFICANTLY AFFECT ANTICIPATED RESULTS IN THE FUTURE, AND ACCORDINGLY, SUCH RESULTS MAY DIFFER MATERIALLY FROM THOSE EXPRESSED IN ANY FORWARD-LOOKING STATEMENTS MADE BY OR ON BEHALF OF BIOMERICA. THE POTENTIAL RISKS AND UNCERTAINTIES INCLUDE, AMONG OTHERS, FLUCTUATIONS IN THE COMPANY'S OPERATING RESULTS. THESE RISKS AND UNCERTAINTIES ALSO INCLUDE THE SUCCESS OF THE COMPANY IN RAISING NEEDED CAPITAL, THE ABILITY OF THE COMPANY TO MAINTAIN REQUIREMENTS TO BE LISTED ON NASDAQ, THE CONTINUAL DEMAND FOR THE COMPANY'S PRODUCTS,

Edgar Filing: BIOMERICA INC - Form 10-Q

COMPETITIVE AND ECONOMIC FACTORS OF THE MARKETPLACE, AVAILABILITY OF RAW MATERIALS, HEALTH CARE REGULATIONS AND THE STATE OF THE ECONOMY. READERS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE HEREOF, AND THE COMPANY UNDERTAKES NO OBLIGATION TO UPDATE THESE FORWARD-LOOKING STATEMENTS.

RESULTS OF OPERATIONS

Consolidated net sales for Biomerica were \$1,194,345 for the first quarter of fiscal 2009 as compared to \$1,340,065 for the same period in the previous year. This represents a decrease of \$145,720 or 10.9% for the quarter ended August 31, 2008 as compared to the quarter ended August 31, 2007. The decrease was primarily due to less screening programs being conducted by certain drug stores this quarter which resulted in lower sales of the EZ Detect product.

Cost of sales in the first quarter of fiscal 2009 were \$661,216, or 55.4% of sales as compared to \$735,621, or 54.9% of sales in fiscal 2008. Cost of sales as a percentage of sales in fiscal 2008 increased by .5%.

Selling, general and administrative costs increased by \$18,600, or 5.8% for the period ended August 31, 2008 as compared to the period ended August 31, 2007. The increase was primarily the result of higher wages and accounting related to our SOX 404 project. Research and development decreased by \$22,756, or 32.6% for period ended August 31, 2008 as compared to the period ended August 31, 2007, due to a reduction in personnel and lower materials costs. The decrease in personnel and materials cost was temporary and should increase again in the second quarter as work on certain research projects intensifies.

For the three months ended August 31, 2008, other income of \$12,022 was realized as compared to \$707,754 in the same period in the prior fiscal year. This decrease was due to one-time benefit of \$697,034 in fiscal 2008, which was realized from the sale of a marketable security which had been carried on the Company's books at zero. The balance of the increase was due to interest income on the Company's cash balances.

Interest income, net of interest expense, decreased by \$2,872 due to lower interest expense due to lower balances on notes.

LIQUIDITY AND CAPITAL RESOURCES

As of August 31 and May 31, 2008, the Company had cash and available-for-sale securities in the amount of \$1,961,206 and \$2,022,735 and working capital of \$3,568,227 and \$3,428,936, respectively.

10

During the quarter ended August 31, 2008 the Company operations provided cash of \$49,595 as compared to \$477,616 in the prior fiscal year. The decrease was primarily due to the one-time other income of \$707,754 in fiscal 2008 as well as an increase in inventory during the current year of \$209,515, which was partially offset by the collection on accounts receivable of \$327,035. Cash used by financing activities in fiscal 2009 was \$78,387 as compared to cash provided by financing activities for fiscal 2008 of \$1,632. The major reason for this increase was the \$95,936 used to pay off the shareholder note. The Company invested \$32,762 in the purchase of fixed assets in fiscal 2009 as compared to \$5,588 in the prior fiscal year.

In February 2007 the Company obtained a \$200,000 working capital line of credit and was approved for a \$200,000 equipment loan with Commercial Bank of

Edgar Filing: BIOMERICA INC - Form 10-Q

California. The credit line and the equipment loan are collateralized by substantially all of the assets of the Company. As of August 31, 2008 \$151,846 was owed on the equipment loan and there was no outstanding balance due on the working capital line of credit. In August 2008 Commercial Bank of California extended the expiration date on the line of credit of \$200,000, which was scheduled to expire September 1, 2008, until November 1, 2008, while terms of a new line of credit can be evaluated by both parties.

CRITICAL ACCOUNTING POLICIES

The discussion and analysis of our financial condition and results of operations are based on the consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. Note 2 of the Notes to Consolidated Financial Statements contained in the Company's annual report on Form 10KSB for the period ended May 31, 2008, describes the significant accounting policies essential to the consolidated financial statements. The preparation of these financial statements requires estimates and assumptions that affect the reported amounts and disclosures.

We believe the following to be critical accounting policies as they require more significant judgments and estimates used in the preparation of our consolidated financial statements. Although we believe that our judgments and estimates are appropriate and correct, actual future results may differ from our estimates.

In general the critical accounting policies that may require judgments or estimates relate specifically to the Allowance for Doubtful Accounts, Inventory Reserves for Obsolescence and Declines in Market Value, Impairment of Long-Lived Assets, Stock Based Compensation and Income Tax Accruals.

Revenues from product sales are recognized at the time the product is shipped, customarily FOB shipping point, at which point title passes. When necessary an allowance is established for estimated returns as revenue is recognized.

The Allowance for Doubtful Accounts is established for estimated losses resulting from the inability of our customers to make required payments. The assessment of specific receivable balances and required reserves is performed by management and discussed with the audit committee. We have identified specific customers where collection is not probable and have established specific reserves, but to the extent collection is made, the allowance will be released. Additionally, if the financial condition of our customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required.

11

Reserves are provided for excess and obsolete inventory, which are estimated based on a comparison of the quantity and cost of inventory on hand to management's forecast of customer demand. Customer demand is dependent on many factors and requires us to use significant judgment in our forecasting process. We must also make assumptions regarding the rate at which new products will be accepted in the marketplace and at which customers will transition from older products to newer products. Once a reserve is established, it is maintained until the product to which it relates is sold or otherwise disposed of, even if in subsequent periods we forecast demand for the product.

Historically we were in a loss position for tax purposes, and established a valuation allowance against deferred tax assets, as we did not

Edgar Filing: BIOMERICA INC - Form 10-Q

believe it was likely that we would generate sufficient taxable income in future periods to realize the benefit of our deferred tax assets. Although the Company has achieved net income in increasing amounts over the last three fiscal years, predicting future taxable income is difficult, and requires the use of significant judgment. Due to the fact that many factors can influence profitability, management determined at May 31, 2008, that \$170,000 of previously allowed for deferred tax assets should be released, which resulted in an income tax benefit of \$170,000 being recognized during fiscal year end May 31, 2008. Management re-evaluated this at August 31, 2008 and determined that the deferred tax asset should remain at \$170,000.

The Company has historically classified income from freight charges to customers as sales, which has been offset by shipping and handling costs. The income from freight for the quarters ended August 31, 2008 and 2007, respectively, was \$24,872 and \$34,893. The financial statements presented herein show the income from shipping and handling as a component of sales for both periods and the costs of shipping and handling as a component of cost of goods sold.

Please refer to the annual report on Form 10-KSB for the period ended May 31, 2008 for an in-depth discussion of risk factors.

FACTORS THAT MAY AFFECT FUTURE RESULTS

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

You should read the following factors in conjunction with the factors discussed elsewhere in this and our other filings with the SEC and in materials incorporated by reference in these filings. The following is intended to highlight certain factors that may affect the financial condition and results of operations of Biomerica and are not meant to be an exhaustive discussion of risks that apply to companies such as Biomerica. Like other businesses, Biomerica is susceptible to macroeconomic downturns in the United States or abroad, that may affect the general economic climate and performance of Biomerica or its' customers. Aside from general macroeconomic downturns, the additional material factors that could affect future financial results include, but are not limited to: Terrorist attacks and the impact of such events; diminished access to raw materials that directly enter into our manufacturing process; shipping labor disruption or other major degradation of the ability to ship our products to end users; inability to successfully control our margins which are affected by many factors including competition and product mix; protracted shutdown of the U.S. Border due to an escalation of terrorist or counter terrorist activity; any changes in our business relationships with international distributors or the economic climate they operate in; any event that has a material adverse impact on our foreign manufacturing operations may adversely affect our operation as a whole; failure to manage the future expansion of our business could have an adverse affect on our revenues and profitability; possible costs in complying with government regulations and the delays in receiving required regulatory approvals or the enactment of new adverse regulations or regulatory requirements; numerous competitors, most of which have substantially greater financial and other resources than we do; potential claims and litigation brought by patients or medical professionals alleging harm caused by the use of or exposure to our products; quarterly variations in operating results caused by a number of factors, including business and industry conditions and other factors beyond our control. All of these factors make it difficult to predict operating results for any particular period.

Edgar Filing: BIOMERICA INC - Form 10-Q

Item 4. CONTROLS AND PROCEDURES

The Company's Chief Executive Officer and Chief Financial Officer (the Company's principal executive officer and principal financial officer, respectively) have concluded, based on their evaluation as of August 31, 2008, that the design and operation of the Company's "disclosure controls and procedures" (as defined in rules 13a-15(e) under the Securities Exchange Act of 1934, as amended ("Exchange Act")) are effective to ensure that information required to be disclosed by the Company in the reports filed or submitted by the Company under the Exchange Act is accumulated, recorded, processed, summarized and reported to the Company's management, including the Company's principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding whether or not disclosure is required.

During the quarter ended August 31, 2008, there were no changes in the Company's "internal controls over financial reporting" (as defined in Rule 13a-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, the Company's internal controls over financial reporting.

13

PART II. OTHER INFORMATION

Item 1. LEGAL PROCEEDINGS. None.

Item 1A. RISKS AND UNCERTAINTIES.

You should read the following factors in conjunction with the factors discussed elsewhere in this and our other filings with the Securities and Exchange Commission and in materials incorporated by reference in these filings. The following is intended to highlight certain factors that may affect the financial condition and results of operations of Biomerica, Inc. and are not meant to be an exhaustive discussion of risks that apply to companies such as Biomerica, Inc. Like other businesses, Biomerica, Inc. is susceptible to macroeconomic downturns in the United States or abroad, as were experienced in fiscal year 2002, that may affect the general economic climate and performance of Biomerica, Inc. or its customers.

Aside from general macroeconomic downturns, the additional material factors that could affect future financial results include, but are not limited to: Terrorist attacks and the impact of such events; diminished access to raw materials that directly enter into our manufacturing process; shipping labor disruption or other major degradation of the ability to ship out products to end users; inability to successfully control our margins which are affected by many factors including competition and product mix; protracted shutdown of the U.S. border due to an escalation of terrorist or counter terrorist activity; any changes in our business relationships with international distributors or the economic climate they operate in; any event that has a material adverse impact on our foreign manufacturing operations may adversely affect our operations as a whole; failure to manage the future expansion of our business could have a material adverse affect on our revenues and profitability; possible costs in complying with government regulations and the delays in receiving required regulatory approvals or the enactment of new adverse regulations or regulatory requirements; numerous competitors, some of which have substantially greater financial and other resources than we do; potential claims and litigation brought by patients or medical professionals alleging harm caused by the use of or exposure to our products; quarterly variations in operating results caused by a number of factors, including business and industry conditions; concentrations of sales with certain distributions could adversely affect the results of the

Edgar Filing: BIOMERICA INC - Form 10-Q

Company if the Company were to lose the sales of that distributor and other factors beyond our control. All these factors make it difficult to predict operating results for any particular period.

Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS. None.

Item 3. DEFAULTS UPON SENIOR SECURITIES. None.

Item 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS. None.

Item 5. OTHER INFORMATION. None.

Item 6. EXHIBITS.

31.1 Certification Pursuant to Section 302 of the Sarbanes-Oxley Act
- Zackary S. Irani.

31.2 Certification Pursuant to Section 302 of the Sarbanes-Oxley Act
- Janet Moore.

32.1 Certification Pursuant to Section 906 of the Sarbanes-Oxley Act
- Zackary S. Irani.

32.2 Certification Pursuant to Section 906 of the Sarbanes-Oxley Act
- Janet Moore.

14

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has fully caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: October 15, 2008

BIOMERICA, INC.

By: /S/ Zackary S. Irani

Zackary S. Irani
Chief Executive Officer

15